NOVOLIN 70/30 OTC
Generic Name and Formulations:
Insulin isophane suspension (NPH) 70% (human, rDNA origin), regular insulin 30% (human, rDNA origin) 100 Units/mL; inj.
Indications for NOVOLIN 70/30:
Adults and Children:
SC injection only. Onset approx 30 mins, peak 2–12hrs, duration approx 24hrs.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share needles or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide), oral hypoglycemic agents, anabolic steroids, quinine, quinidine, alpha-adrenergic blocking agents. Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics, oral contraceptives, thyroid hormones, growth hormone, diazoxide, asparaginase, nicotinic acid. Variable effects with β-blockers, clonidine, lithium salts, alcohol.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.